Eli Lilly (LLY) said Friday it completed its $3.2 billion acquisition of Morphic Holding (MORF).
Morphic shares will now be delisted from the Nasdaq Global Market, Lilly said
Lilly acquired Morphic, a biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases, for $57 per share in cash.
Price: 911.75, Change: +3.70, Percent Change: +0.41
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments